We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cambridge Cognition Holdings Plc | COG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 32.50 | 07:34:46 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 32.50 | 32.50 | 32.50 | 32.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 01/6/2025 01:33 by 40 fathoms Cancellations are an inherent aspect of any CROs business, even more particularly those with a CNS focus. That said COG is not a CRO it is a trial technology provider, which provides associated services it is not responsible for conducting any clinical trails.This difference is slightly semantic but it does benefit COG over that of a CRO, and that is that a substantial portion of cash received from a contract, approximately 30% to 40%, originates from the initial sale of the software license, and this is paid at the start of the trial and is not refundable. This is not the case with a CRO. Furthermore, it is evident that there has been a significant reduction in concentration over the past two years, both with respect to clients, indication and to individual trials. |
Posted at 30/5/2025 20:42 by earwacks It is quite alarming actually not because it necessarily follows on that Cog might face its own headwinds. Cog do brain health. Hvivo do infectious and respiratory diseases. After Covid I thought they were supposed to be doubling up efforts in researching viruses. Cogs closest competitor had a strong first half as did Cog returning to growth with a strong pipeline. Trumpenomics is creating big problems. Cog currently operate in over 100 countries. |
Posted at 30/5/2025 14:11 by cerrito By chance I read the TS this morning of the CRO HVO, about who I know nothing, and saw cancellations of clinical trials, citing volatility in the pharmaceutical industry.Given in the last 2 years, clinical studies have represented more than 90pc of COG's revenue I ask myself what impact this volatility will have on COG. |
Posted at 13/4/2025 01:56 by 40 fathoms I was reading this week’s RNS to try and identify the contract’s sponsor, and I noticed something I overlooked the first time."Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial. The initial contract, starting in 2025 and running through to 2031, is valued at approximately £1 million. The Company has previously provided services to this customer, and this represents repeat business with this global company." The term "initial contract" with an existing customer would to my mind signal the possibility of further such contracts in the future. |
Posted at 03/4/2025 11:45 by 40 fathoms I wonder if this is for J&Js Spravato (esketamine)?It appears that COG will not be a primary or secondary endpoint, but rather an exploratory endpoint. This explains the relatively low value of the contract, considering it is for two-phase III trials. Additionally, it would account what they have been brought in to a Phase 3 without working on the Phase 2 as they will be able to validate against a well-understood API. If successful, in the long-term, this would have substantial value for COG. J&J has an extensive Neuroscience pipeline. |
Posted at 25/2/2025 21:33 by bedford1976 My linkedin had a new post today about Monument Therapeutics they have another 850k for the schizophrenia development. This must be quite lucrative pipeline they certainly don't seem to have any issues fundraising No mention regarding Cam Cog or dilution. |
Posted at 17/1/2025 12:01 by 40 fathoms The real significance of yesterday's RNS has only just dawned on me. Cambridge Cognition won all the cognitive measurement, data capture, and quality control work for the entire trial, even though CANTAB is only a secondary endpoint. The primary endpoint, CDR-SB, must be administered by a rater, usually a clinical psychologist.This is significant because, before the acquisition of Clinpal and Winterlight (24 months ago) and subsequent product development, Cambridge Cognition could have only provide the secondary endpoint for this trial. It is interesting and significant that Cambridge Cognition replaced Cogstate, which had provided the non-eCOA work in earlier trials. Normally, I would not pay too much attention to this; however, in Alzheimer's Disease (AD), Cogstate is the dominant player and has digital offerings so this is significant. This hints at a significant increase in the potential opportunity set in other trials/indications where rater based scales are used as primary endpoints and AQUA is relevant such as PANNS, ADAS-COG, HAM-A, HAM-D etc and where a CANTAB battery may only be an exploratory or secondary endpoint. |
Posted at 11/12/2024 03:24 by 40 fathoms Having read the updates from Dowgate and PL. One key point I noted is that both have forecasted a lower revenue number than management's forecast @12.5 mn and 12.6 mn respectively. PL's note states that management is targeting a 30% to 40% increase in revenue for FY25 over FY24, but PL has chosen to take a more conservative approach.If COG achieves the top end of management's target (40%), it would align closely with the previous FY25 revenue forecast PL had at the interims. To me this suggests a general shift in revenue expectations to the right, rather than a change in the shape of the overall revenue outlook. The cash draw in the second half versus a breakeven adjusted EBITDA is a bit harder to figure out. £600k will go towards the monthly repayments of the Claret Loan, and £137.5k will cover interest on that loan. This leaves approximately £1.6 million. There might be some restructuring costs related to the CEO and CFO departures, but the significant balance is likely working capital. This is probably accounted for by the difference between invoicing (and thus revenue recognition on new contracts won late in the year) and cash collection. If correct, this will convert back to cash early in FY25 and may explain the confident tone in the RNS; this situation will further improve with additional contract wins. |
Posted at 10/12/2024 14:17 by earwacks COG gets a mention by a certain commentator as a company worth looking at.’worried about its ability to scale up.’ I would not have thought that as an issue, more about its ability to confirm orders. Anyone know what the margins are for Cog ? Usually pretty good for unique specialist software |
Posted at 05/9/2024 13:33 by 40 fathoms This was posted today, no RNS but interesting nonetheless.Don't seem able to post the link, so here is a copy of the text "US patient recruitment firm Splash Clinical has teamed up with UK-based digital brain health services provider Cambridge Cognition (COG) to help sponsors find people to participate in central nervous system (CNS)-focused drug trials. The new partnership – financial terms of which were not disclosed – will see Splash utilize COG’s pre-screening technology to assess potential participants for studies focusing on CNS indications. In a press statement, Splash CEO Matt Teuteberg, said, “By integrating their assessment tools into our platform, we will increase our efficiency in finding the right patients for clinical trials. This partnership will save time and resources for our clients and ultimately make treatments available for patients faster.” CNS recruitment Finding the right patients to take part in drug research is always difficult, nonetheless of the disease involved. Recruiting for trials focusing on neurological disorders is a particular challenge. For example, a 2023 study in the journal Innovations in Clinical Neuroscience suggested the lack of information about CNS patients combined with the nature of the diseases themselves are the issue. “In contrast to other therapeutic areas, such as oncology or cardiovascular diseases, there are no large clinical research networks for CNS, making it more difficult to efficiently reach patients in their care setting. There are also challenges associated with CNS disorders themselves that are not relevant to other therapeutic areas … Thus, the timely recruitment and retention of the right and representative patients is a challenge for CNS clinical trials.” COG’s technology is designed to address such difficulties. The system consists of an online cognitive assessment portal that gathers and processes data from potential study participants. According to the firm, the assessment, which takes around ten minutes, reduces screening failures and increases the quality of patients entering the trial. Splash said that, in combination with its own suite or recruitment tools, the new tech will help it reach a broader population while maintaining high-quality standards. Liam Kaufman, Cambridge Cognition’s vice president of clinical sciences, emphasized the potential benefits of the collaboration, explaining “They’ve got a great recruitment platform and a solid track record in recruitment. Our tools complement their process perfectly. Our goal is to make it easier for researchers to find the right participants for their CNS trials. It’s a win-win for everyone involved.” She added that during a pilot collaboration completed last year, COG’s software helped filter in hard-to-find patients with early Alzheimer’s symptoms. News of the collaboration comes a few months after the Michael J. Fox Foundation began using COG’s technology to identify the cognitive profile of Parkinson’s Disease patients as part of an effort to identify biomarkers – and potential druggable targets – for the condition. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
